Recent Stage I/Smoldering Myeloma Multiple Myeloma News

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes

(February 3, 2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

(December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma

(December 8, 2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma

(March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results... Continue Reading

Early Treatment of Multiple Myeloma Slows Progression

(August 30, 2013)

Early treatment with Revlimid® (lenalidomide) and dexamethasone for patients with high-risk smoldering multiple myeloma delays progression to active disease and increases overall survival, according to... Continue Reading

Carfilzomib Promising in Newly Diagnosed Multiple Myeloma

(March 13, 2012)

The investigational drug carfilzomib, in combination with Revlimid® (lenalidomide) and low-dose dexamethasone, produced high response rates in patients with newly diagnosed myeloma. The results of this... Continue Reading

Continuous Revlimid May Improve Outcomes in Newly Diagnosed Multiple Myeloma

(December 15, 2010)

Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may result... Continue Reading

Revlimid Maintenance Slows Myeloma Progression After Stem Cell Transplant

(December 14, 2010)

Maintenance therapy with Revlimid® (lenalidomide) reduced the risk of myeloma progression or death by 60% among patients who had undergone an autologous stem cell transplant. These updated results from... Continue Reading

Improved Survival with Zometa in Multiple Myeloma

(December 14, 2010)

It appears that treatment of patients with newly diagnosed multiple myeloma with Zometa® (zoledronic acid) may improve overall survival and progression-free survival. These findings were recently reported... Continue Reading

Combination of Velcade and Revlimid Promising Against Newly Diagnosed Multiple Myeloma

(October 29, 2010)

Among patients with symptomatic newly diagnosed multiple myeloma, treatment with a combination of Revlimid® (lenalidomide), Velcade® (bortezomib), and dexamethasone produced a partial response or better... Continue Reading

Next Page »